ALVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ALVO is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading weakly, recent earnings showed declining revenue, analysts are turning more cautious with lower price targets, and there is no strong proprietary buy signal today. I would not buy it at the current price; the better decision is to wait.
ALVO is in a bearish technical setup. The stock closed at 3.197 after a sharp regular-session drop of 10.36%, and it is also below the pivot level of 3.398. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which signals a downtrend. RSI_6 at 32.277 is near oversold but not a clean reversal signal. MACD histogram is slightly positive at 0.00357 but contracting, so momentum is not confirming a strong rebound. Key support is 3.232 and then 3.129, while resistance is 3.564 and 3.667. Overall trend remains weak.
Q4 2025 showed revenue growth of 10.14% year over year and gross margin improved to 63.72%. The company still has a favorable long-term biosimilars narrative, and UBS remains constructive with a Buy rating, expecting approvals by year-end 2026 and believing the stock has reset after negative developments. The news also notes that gross margin stayed strong at 57% in Q1 despite lower revenue, which suggests some cost discipline.
The stock also saw a sharp daily selloff, and hedge fund and insider trading trends are neutral with no meaningful accumulation. No recent congress trading data and no notable politician/influencer buying support were provided.
Latest quarter shown is Q1 2026. Revenue was $105.9 million, down 20.3% year over year and below expectations by $34.95 million. Adjusted EBITDA was $24.4 million, indicating weaker profitability than the prior year. Gross margin remained solid at 57%, which is a positive sign for operating efficiency, but the top-line decline is the dominant takeaway. The financial snapshot for Q4 2025 had revenue up 10.14% year over year to 168.895 million, but net income was still negative at -108.547 million and EPS remained negative at -0.38, so profitability is still not consistently strong.
Analyst sentiment is mixed to cautious, but the trend is clearly weakening. Deutsche Bank cut its target to $4 from $8 and kept Hold. Barclays cut its target to $4 from $5 and kept Underweight, saying the stock may stay in a holding pattern until U.S. approvals in Q4 2026 and noting leverage and financial flexibility concerns. UBS is still positive with a Buy rating, but it lowered its target to $6 from $10. Overall, Wall Street is more cautious than bullish right now, with the pro side focused on long-term biosimilars potential and eventual approvals, while the con side emphasizes leverage, delayed catalysts, and weak near-term execution.
